At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 186 enrolled
Drug / intervention
Atogepant 60 mgdrug
Likely dose
Atogepant 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-Label 52-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
In Brief
A Phase 3 clinical trial evaluating Atogepant 60 mg for Chronic Migraine and Episodic Migraine. Completed, enrolled 186 participants across 24 sites.
Detailed Summary
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine, Episodic Migraine
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionJun 2024
TodayJul 2026
First PostedJun 18, 2020
Enrollment StartJun 18, 2020
Primary CompletionJun 11, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.0 years ago
Interventions
Atogepant 60 mgdrug
Tablets containing 60 mg atogepant